From the San Antonio Military Medical Center, Fort Sam Houston, TX, USA (P.M. Grogan); Center for Neurological Care and Research, San Antonio, TX, USA (M.V. Alvarez); Department of Neurology, Mayo Clinic, Rochester, MN, USA (L. Jones).
Headache Direction and Aura Predict Migraine Responsiveness to Rimabotulinumtoxin B
Article first published online: 5 NOV 2012
© 2012 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 53, Issue 1, pages 126–136, January 2013
How to Cite
Grogan, P. M., Alvarez, M. V. and Jones, L. (2013), Headache Direction and Aura Predict Migraine Responsiveness to Rimabotulinumtoxin B. Headache: The Journal of Head and Face Pain, 53: 126–136. doi: 10.1111/j.1526-4610.2012.02288.x
The opinions expressed in this document are solely those of the authors and do not represent an endorsement by or the views of the United States Air Force, the United States Army, Department of Defense, or the United States Government.
Financial support: There was no financial support to fund this study.
Conflict of Interest: Dr. Grogan has received speaker honoraria compensation from Pfizer Inc and US World Meds. Dr. Alvarez has received speaker honoraria compensation from Teva, Pfizer Inc, and US World Meds. Dr. Jones has no financial disclosures. The authors have no conflicts of interest with this study.
- Issue published online: 8 JAN 2013
- Article first published online: 5 NOV 2012
- Manuscript Accepted: 7 AUG 2012
This article has been cited by:
- 1Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: A retrospective study, Journal of the Chinese Medical Association, 2014, 77, 1, 10, , , , ,
- You have free access to this content2